BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, Borruel N. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:762-769. [PMID: 22517240 DOI: 10.1097/meg.0b013e32835414b2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Katsanos KH, Koutroumpakis E, Giagkou E, Malakos Z, Almpani E, Skamnelos A, Christodoulou DK. Fast-track drug approval in inflammatory bowel diseases. Ann Gastroenterol 2016;29:439-44. [PMID: 27708508 DOI: 10.20524/aog.2016.0051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Mawe GM. Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon. J Clin Invest. 2015;125:949-955. [PMID: 25729851 DOI: 10.1172/jci76306] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
3 Zhang C, Liu LW, Sun WJ, Qin SH, Qin LZ, Wang X. Expressions of E-cadherin, p120ctn, β-catenin and NF-κB in ulcerative colitis. J Huazhong Univ Sci Technolog Med Sci 2015;35:368-73. [PMID: 26072075 DOI: 10.1007/s11596-015-1439-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
4 Yamada K, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Kawashima H, Honda T, Ishigami M, Fujishiro M. Diagnostic yield of colon capsule endoscopy for Crohn's disease lesions in the whole gastrointestinal tract. BMC Gastroenterol 2021;21:75. [PMID: 33593297 DOI: 10.1186/s12876-021-01657-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R, Lasch K. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther 2017;45:264-75. [PMID: 27859410 DOI: 10.1111/apt.13852] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
6 Calvet X, Argüelles-Arias F, López-Sanromán A, Cea-Calvo L, Juliá B, de Santos CR, Carpio D. Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain. Patient Prefer Adherence 2018;12:1815-23. [PMID: 30271125 DOI: 10.2147/PPA.S175026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cohen BL, Zoëga H, Shah SA, Leleiko N, Lidofsky S, Bright R, Flowers N, Law M, Moniz H, Merrick M, Sands BE. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther 2014;39:811-22. [PMID: 24612278 DOI: 10.1111/apt.12659] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
8 孙晋洁, 翟晓峰. 心理社会因素与炎症性肠病患者生存质量的关系. 世界华人消化杂志 2014; 22(30): 4695-4700 [DOI: 10.11569/wcjd.v22.i30.4695] [Reference Citation Analysis]
9 Nocerino A, Nguyen A, Agrawal M, Mone A, Lakhani K, Swaminath A. Fatigue in Inflammatory Bowel Diseases: Etiologies and Management. Adv Ther 2020;37:97-112. [PMID: 31760611 DOI: 10.1007/s12325-019-01151-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
10 Frasca JD, Cheifetz AS. The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. Ann Transl Med 2019;7:S388. [PMID: 32016106 DOI: 10.21037/atm.2019.12.86] [Reference Citation Analysis]
11 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
12 Arvanitis M, DeWalt DA, Martin CF, Long MD, Chen W, Jaeger B, Sandler RS, Kappelman MD. Patient-Reported Outcomes Measurement Information System in Children with Crohn's Disease. J Pediatr 2016;174:153-159.e2. [PMID: 27157449 DOI: 10.1016/j.jpeds.2016.03.069] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
13 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Cazzato G, Colagrande A, Andriola V, Lettini T, Cicco S, Candance PMV, Resta L, Vincenti L, Ingravallo G. Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives. Diagnostics (Basel) 2021;11:1570. [PMID: 34573912 DOI: 10.3390/diagnostics11091570] [Reference Citation Analysis]
15 Gollifer RM, Menys A, Makanyanga J, Puylaert CA, Vos FM, Stoker J, Atkinson D, Taylor SA. Relationship between MRI quantified small bowel motility and abdominal symptoms in Crohn's disease patients-a validation study. Br J Radiol 2018;91:20170914. [PMID: 29888980 DOI: 10.1259/bjr.20170914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 王承党, 郭晓雄. 炎症性肠病治疗的理想目标: 深度缓解的意义和对策. 世界华人消化杂志 2015; 23(24): 3824-3830 [DOI: 10.11569/wcjd.v23.i24.3824] [Reference Citation Analysis]
17 Bekheit M, Baddour N, Katri K, Taher Y, El Tobgy K, Mousa E. Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series. BMJ Open Gastroenterol. 2016;3:e000082. [PMID: 27195128 DOI: 10.1136/bmjgast-2016-000082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
18 Kanmura S, Hamamoto H, Tanaka A, Arima S, Sasaki F, Tanoue S, Nasu Y, Hashimoto S, Higashi M, Ido A. Diagnostic utility of linked color imaging in the evaluation of colonic mucosal inflammation in ulcerative colitis: a pilot study. Endosc Int Open 2019;7:E937-43. [PMID: 31367672 DOI: 10.1055/a-0810-0398] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Shah J, Thakur ML, Dutta U. Mucosal healing in inflammatory bowel disease: Expanding horizon. Indian J Gastroenterol 2019;38:98-109. [PMID: 31037509 DOI: 10.1007/s12664-019-00950-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gong SS, Fan YH, Lv B, Zhang MQ, Xu Y, Zhao J. Fatigue in patients with inflammatory bowel disease in Eastern China. World J Gastroenterol 2021; 27(11): 1076-1089 [PMID: 33776374 DOI: 10.3748/wjg.v27.i11.1076] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
22 AlRuthia Y, Alharbi O, Aljebreen AM, Azzam NA, Almadi MA, Bahari OH, Almalki KA, Atham AT, Alanazi AS, Saeed M, HajkhderMullaissa B, Alsenaidy M, Balkhi B. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Eff Resour Alloc 2019;17:25. [PMID: 31827409 DOI: 10.1186/s12962-019-0194-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis 2018;12:145-56. [PMID: 29028981 DOI: 10.1093/ecco-jcc/jjx133] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 15.0] [Reference Citation Analysis]
24 Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, Barreiro-de Acosta M. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. Int J Environ Res Public Health 2021;18:7159. [PMID: 34281095 DOI: 10.3390/ijerph18137159] [Reference Citation Analysis]
25 Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol 2014;20:81-101. [PMID: 24705146 DOI: 10.4103/1319-3767.129473] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]